Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite ...

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chr ...
EuropaWire

Empa Secures Werner Siemens Foundation Funding to Develop SonoGuard Postoperative Monitoring Technology

Empa researcher Inge Herrmann has secured 8 million Swiss francs in funding from the Werner Siemens Foundation to develop SonoGuard, a novel system designed to detect and treat complications after ...
Santé log

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

In the U.S., a supplemental Biologics License Application (sBLA) has been accepted for review seeking approval for Dupixent in certain children aged 2 to 11 years with CSU. The U.S. Food and Drug ...